RayKnowChina Research Map
Shortlist

Tianjin

First Teaching Hospital, Tianjin University of Traditional Chinese Medicine

天津中医药大学第一附属医院

Listed for 5 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Teaching Hospital, Tianjin University of Traditional Chinese Medicine

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Lung cancer肺癌26 papers led4 open trials led
  2. Breast cancer乳腺癌5 papers led4 open trials led
  3. Multiple myeloma多发性骨髓瘤3 papers led
  4. Coronary heart disease冠心病6 papers led
  5. IgA nephropathyIgA 肾病1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Lung cancer

肺癌

Led 26 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
26
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 101020232024: 6620242025: 332025

7 hospitals in Tianjin for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07034326

    Age 18 years to 80 years (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

  2. Recruiting
    Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07086300

    Age 65 years to 100 years (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

  3. Recruiting
    Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07239661

    Age 18 years to Not stated (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

  4. Recruiting
    Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06548711

    Age 18 years to 80 years (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRheumatology & immunologyPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led26
  1. From autoimmune inflammation to malignancy: causal genetic evidence for the RA-squamous cell lung cancer axis.2025Arthritis research & therapyFree full text
  2. Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.2025Journal of cancer research and clinical oncologyFree full text
  3. Association between advanced lung cancer inflammation index and cognitive function among US older adults from a cross-sectional survey of the NHANES 2011 to 2014.2025MedicineFree full text
  4. Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.2024Cancer immunology, immunotherapy : CIIFree full text
  5. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis.2024Current cancer drug targets
  6. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review.2024International immunopharmacology
  7. Immunosenescence and immunotherapy in older NSCLC patients.2024Journal of cancer research and therapeutics
  8. Study of the mechanism by which Xiaoyan decoction combined with E7449 regulates tumorigenesis in lung adenocarcinoma.2024Journal of cellular and molecular medicineFree full text
  9. Identification and analysis of prognostic immune cell homeostasis characteristics in lung adenocarcinoma.2024The clinical respiratory journalFree full text
  10. Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges.2023Anti-cancer drugs
  11. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.2023Anti-cancer drugs
  12. Advances in immune checkpoint inhibitors therapy for small cell lung cancer.2023Cancer medicineFree full text
  13. The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer.2023Immunity, inflammation and diseaseFree full text
  14. A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer.2023International immunopharmacology
  15. Combination Treatment with Iodine 125 Seeds Implant and Systemic Therapy vs. Systemic Therapy Alone for Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.2023Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  16. A novel long noncoding RNA (lncRNA), LINC02657(LASTR), is a prognostic biomarker associated with immune infiltrates of lung adenocarcinoma based on unsupervised cluster analysis.2023PeerJFree full text
  17. RGN as a prognostic biomarker with immune infiltration and ceRNA in lung squamous cell carcinoma.2023Scientific reportsFree full text
  18. Autophagy and Glycometabolic Reprograming in the Malignant Progression of Lung Cancer: A Review.2023Technology in cancer research & treatmentFree full text
  19. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.2023World journal of surgical oncologyFree full text
  20. ADAMTS8 inhibited lung cancer progression through suppressing VEGFA.2022Biochemical and biophysical research communications
  21. Clinical predictive value of naïve and memory T cells in advanced NSCLC.2022Frontiers in immunologyFree full text
  22. Evodiamine suppresses the progression of non-small cell lung carcinoma via endoplasmic reticulum stress-mediated apoptosis pathway in vivo and in vitro.2022International journal of immunopathology and pharmacologyFree full text
  23. A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.2022Oxidative medicine and cellular longevityFree full text
  24. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.2021BioMed research internationalFree full text
  25. Lentinan combined with cisplatin for the treatment of non-small cell lung cancer.2021MedicineFree full text
  26. Is COVID-19 a high risk factor for lung cancer?: A protocol for systematic review and meta-analysis.2021MedicineFree full text
Chinese-language papers (not in the count)3
  1. [Research Progress on Immunosenescence in Elderly Patients 
with Advanced Non-small Cell Lung Cancer and Its Immunotherapy].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  3. [Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLCRecruitingNCT07086300Lead (inferred)N/AStart 2025-07
  2. Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLCRecruitingNCT07239661Lead (inferred)N/AStart 2025-11
  3. Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung CancerRecruitingNCT07034326Lead (inferred)Phase 2/Phase 3Start 2025-01
  4. Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung CancerRecruitingNCT06548711Lead (inferred)N/AStart 2024-04

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 5 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.03%.

Papers led
5
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 222025

4 hospitals in Tianjin for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07490938

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesTianjin, Wuhan, Xining

  2. Recruiting
    Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07763587

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 1 listed hospital as study siteTianjin

  3. Not yet recruiting
    Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07481903

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesBeijing, Nanjing, Tianjin

  4. Not yet recruiting
    Study on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07942103

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led5
  1. Breast cancer-targeted therapy and doxorubicin multidrug resistance are reversed via macrophage membrane-camouflaged liposomes.2025Colloids and surfaces. B, Biointerfaces
  2. Expression of G-quadruplex coordinates BRCA1, CDH1, and RASSF1 via DNA methylation in mouse breast cancer cells.2025EpigenomicsFree full text
  3. HER3 receptor and its role in the therapeutic management of metastatic breast cancer.2024Journal of translational medicineFree full text
  4. Effects of Acupuncture on Breast Cancer Patients Taking Aromatase Inhibitors.2022BioMed research internationalFree full text
  5. The Predictive Value of Changes in the Absolute Counts of Peripheral Lymphocyte Subsets for Progression and Prognosis in Breast Cancer Patients.2022Contrast media & molecular imagingFree full text
Chinese-language papers (not in the count)1
  1. Acupuncture and moxibustion treatment for breast cancer-related lymphoedema: a systematic review and Meta-analysis.2024Zhen ci yan jiu = Acupuncture research
All its trials on ClinicalTrials.gov, any status4
  1. Study on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer PatientsNot yet recruitingNCT07942103Lead sponsorN/AStart 2026-10
  2. Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management RegimenRecruitingNCT07763587Lead sponsorN/AStart 2026-08
  3. Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer SurvivorsNot yet recruitingNCT07481903Lead sponsorN/AStart 2026-04
  4. Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint PainRecruitingNCT07490938Lead sponsorN/AStart 2026-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 112025

5 hospitals in Tianjin for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskBispecific & antibody drugsDrug combinations

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 6 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

9 hospitals in Tianjin for coronary heart disease231 hospitals in China for coronary heart disease

No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led6
  1. Cardiac lymphatic system and coronary heart disease: associations, mechanisms and therapeutic strategies.2026European journal of pharmacology
  2. Neuro-immune interactions in coronary microvascular disease: mechanisms and therapeutic prospect.2025Frontiers in immunologyFree full text
  3. Qishen Yiqi Dripping Pills for Cardiovascular Diseases: Effects and Mechanisms.2023Chinese journal of integrative medicine
  4. Effects of empowerment education on patients after percutaneous coronary intervention: A meta-analysis and systematic review.2023MedicineFree full text
  5. From Iron Metabolism to Ferroptosis: Pathologic Changes in Coronary Heart Disease.2022Oxidative medicine and cellular longevityFree full text
  6. Protocol to study the effects of Traditional Chinese Medicine on patients with coronary heart disease showing phlegm-heat-stasis symptom pattern.2021Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
Chinese-language papers (not in the count)1
  1. [Current status of randomized controlled trials of traditional Chinese medicine in treating coronary heart disease with angina pectoris after percutaneous coronary intervention].2024Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
All its trials on ClinicalTrials.gov, any status2
  1. Syndrome Differentiation in the Management of Chronic Stable Coronary Artery Disease (SCAD) to Improve QualityStatus unknownNCT03018769Lead sponsorStart 2016-12
  2. Xuefu-Zhuyu Capsule for the Treatment of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome)Status unknownNCT04218487Study sitePhase 4Start 2019-12

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Tianjin for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

天津中医药大学第一附属医院

First Teaching Hospital, Tianjin University of Traditional Chinese Medicine

天津

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; 中国传统医药的天津大学第一附属医院

Suggest a correctionDownload the data